FDA Accepts New Drug Application for Veverimer Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 14, 2019-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 14, 2019-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 5, 2019-- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its third quarter 2019 financial results after the close of market on Thursday, November 14, 2019 . Tricida will host a conference call and webcast at 4:30 pm Eastern Time

  Management to unveil veverimer (TRC101) U.S. commercialization strategy following recent NDA submission     Leading clinicians and researchers to discuss implications of metabolic acidosis     Live and archived webcast available     SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct.

  SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 2, 2019-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-dosed polymer designed to treat metabolic acidosis in patients

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 12, 2019-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company, announced today the launch of an educational website for healthcare providers. The website, https://metabolicacidosisinsights.com , is an online resource providing essential

NDA Submitted under the FDA’s Accelerated Approval Program SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 4, 2019-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed,

Narrows Timing of Planned NDA Submission to the Third Quarter of 2019 Back-to-Back Publications in ‘The Lancet’ Highlight Positive Clinical Trial Results of Veverimer Webcast Today at 4:30 pm Eastern Time SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 8, 2019-- Tricida, Inc.

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 1, 2019-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in

TRCA-301E trial is the first, long-term, randomized, multicenter, blinded, placebo-controlled trial to evaluate the treatment of metabolic acidosis in patients with CKD SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 25, 2019-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on